Goldman Comments on Shire's (SHPG) Lialda Appeals Court Decision

March 31, 2014 8:45 AM EDT Send to a Friend
Get Alerts SHPG Hot Sheet
Price: $238.52 -0.47%

Rating Summary:
    9 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 19 | New: 16
Trade SHPG Now!
Join SI Premium – FREE
Goldman Sachs maintained a Conviction Buy rating on Shire (NASDAQ: SHPG). Analyst Keyur Parekh commented on Lialda litigation.

"We believe there is significant confusion on what Friday's (March 28) decision from the US Court of Appeals means for Lialda's continued US exclusivity. Based on our conversations with Shire and Actavis as well as historical timelines, we believe a generic Lialda in the US market pre 2016 appears unlikely," said Parekh.

"We continue to see Lialda as a growth driver for Shire and believe impact from any potential generic competition is likely to be modest. In addition, our previous analysis suggests that Shire has enough cost cushion to largely offset any Lialda-related impact on the bottom line," he added.

For an analyst ratings summary and ratings history on Shire click here. For more ratings news on Shire click here.

Shares of Shire closed at $148.22 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Litigation

Related Entities

Goldman Sachs

Add Your Comment